RVX July 30 2024 POV

On July 3 jonzobot wrote - I think the strategy is as stated. They will wait for a Zenith molecule to become derisked enough to sell and use the money to pay for a trial for RVX. It looks like mCRPC (NCT04986423) and NUT carcinoma (NCT05019716) are the most promising candidates for that which are now in phase 2 with completion probably next year some time.

Thanks for the clear explanation jonzobot. I figured that was the plan and it makes my heart sink.

So when I look at the business plan as you outlined it would be patently absurd for me to believe that the business team at RVX could achieve any of it.

1. Don has spoken for years about generating revenue from licensing out molecules for testing and development. Nothing has happened.
2. NUT carcinoma testing is in phase 2 with no reported results to date that I am aware of and the trial is small.
3. If the NUT/zen3694 trial is a success it will take at least a year for FDA approval and then find a way to produce it and get it to market.
4. RVX needs to raise money for a long Covid trial and then raise $150,000,000 for a BoM2 trial (using the average of the BP 5yr proposed trial and the RVX design).
5. If the long Covid trial is successful a couple of years after the money has been raised from the NUT or mCRPC trial, then, there could be a significant flow of cash into RVX in a few years perhaps enough to fund BoM2 for a 3 to 5 years trial.

Therefore, shareholders have many years to wait. This is possibly an opportunity for new investors with 7 years to wait for some ROI but with the current management it’s a very long shot IMHO.

This plan is patently absurd! There is not any chance that this business team at RVX can achieve any of the above goals, at least based on historical evidence.

At any rate the best near term value-adding outcome would be success with NUT and zen3694. With an approved FDA drug, ZCC should be taken public on NASDAQ. That way long-term shareholders can finally be rewarded.

So what will tomorrow bring? My guess is Mr. Excitement will be deeply immersed in forward-looking statements.

Unless we see clear evidence of success of zen3694 in mCRPC or NUT tomorrow we remain in dream mode.

I guess for me what is shocking is that no significant investors have stepped in post BoM, that Eastern has taken a back seat and Hepalink seems also to have lost their enthusiasm. The science seems to have generated academic curiosity but does not seem to have commercial medical application at this stage.

I would love to receive a big “good news” surprise tomorrow but I believe the chances of this are remote.

It is hard for me to imagine how a guy like Don can even face shareholders at this stage. When I bought my initial shares at $7, I was excited to be part of what I thought was going to be break through science by a solid Canadian team. Boy was I wrong on the management side, but I remain hopeful on the science side of things..

GLTA

Toinv